FDA Grants Marketing Authorization to BioFire’s Multiplexed COVID Test – Lines Have Been Drawn

FDA Grants Marketing Authorization to BioFire’s Multiplexed COVID Test – Lines Have Been Drawn

Source: 
FDA Law Blog
snippet: 

On March 17, 2021, FDA granted BioFire Diagnostics’ De Novo, making it the first COVID assay originally authorized on a temporary basis for this public health emergency to be given permanent access to the US market. While FDA has only released the signed letter affirming their permanent marketing status, we can infer a few key points: